Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAN-AKI: Angiotensin II vs noradrenaline for prevention of cardiac surgery-associated acute kidney injury
2024-517771-21-00Phase 4Authorised
- Sponsor
- Universität Münster
- Start
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Angiotensin II in acute kidney failure (AKF) and hypotension (2 arms), sponsored by Universität Münster. Primary endpoint: AKI KDIGO stage 2 or 3 or death within 72 hours after cardiac surgery. Planned start Feb 2025; status: authorised.
02
Drugs
Angiotensin II
03
Conditions
acute kidney failure (AKF)hypotension
Beyond the preview
Go deeper on 2024-517771-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517771-21-00.